Literature DB >> 7316682

Psychiatric disorders in patients with spinal cord injuries.

D T Fullerton, R F Harvey, M H Klein, T Howell.   

Abstract

Although previous studies have reported that all patients with spinal cord injuries experience depression, they have not distinguished between despondency and depressive disorder. Of 30 patients with spinal cord lesions and depressive disorders diagnosed using the Schedule for Affective Disorders and Schizophrenia and the Research Diagnostic Criteria (RDC). 15 patients had RDC diagnoses before or after their injury. A depressive disorder developed in nine after injury. Eight depressive disorders developed within a month of the injury. Postinjury depressive disorders were more common in patients with complete spinal cord lesions but were divided equally between paraplegics and quadriplegics. Only one patient received antidepressants. The remainder recovered without treatment other than the rehabilitation program. The accident causing the injury seemed related to a psychiatric disorder before injury in six patients (four alcoholics and two hypomanics) and to drinking before the accident in 15 patients.

Entities:  

Mesh:

Year:  1981        PMID: 7316682     DOI: 10.1001/archpsyc.1981.01780370071010

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  13 in total

1.  The impact of perceptions of health control and coping modes on negative affect among individuals with spinal cord injuries.

Authors:  Hanoch Livneh; Erin Martz
Journal:  J Clin Psychol Med Settings       Date:  2011-09

2.  Do spinal cord-injured individuals with stronger sense of coherence use different psychological defense styles?

Authors:  J Shakeri; M Yazdanshenas Ghazwin; E Rakizadeh; A Moshari; H Sharbatdaralaei; S Latifi; S A H Tavakoli
Journal:  Spinal Cord       Date:  2015-12-01       Impact factor: 2.772

3.  Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care professionals.

Authors: 
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

4.  Endoplasmic Reticulum Stress and Disrupted Neurogenesis in the Brain Are Associated with Cognitive Impairment and Depressive-Like Behavior after Spinal Cord Injury.

Authors:  Junfang Wu; Zaorui Zhao; Alok Kumar; Marta M Lipinski; David J Loane; Bogdan A Stoica; Alan I Faden
Journal:  J Neurotrauma       Date:  2016-05-16       Impact factor: 5.269

5.  Assessment of depression in a rodent model of spinal cord injury.

Authors:  Kelsey Luedtke; Sioui Maldonado Bouchard; Sarah A Woller; Mary Katherine Funk; Miriam Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

6.  Changes in alcohol use after the onset of spinal cord injury.

Authors:  Janice F Davis; Yue Cao; James S Krause
Journal:  J Spinal Cord Med       Date:  2017-04-26       Impact factor: 1.985

7.  Association among practice frequency on depression and stress among competitive US male wheelchair rugby athletes with tetraplegia.

Authors:  S L Silveira; T Ledoux; M Cottingham; D C Hernandez
Journal:  Spinal Cord       Date:  2017-05-16       Impact factor: 2.772

8.  Inconsistencies with screening for traumatic brain injury in spinal cord injury across the continuum of care.

Authors:  Seema Sikka; Angela Vrooman; Librada Callender; David Salisbury; Monica Bennett; Rita Hamilton; Simon Driver
Journal:  J Spinal Cord Med       Date:  2017-07-31       Impact factor: 1.985

9.  Telehealth: reaching out to newly injured spinal cord patients.

Authors:  V L Phillips; S Vesmarovich; R Hauber; E Wiggers; A Egner
Journal:  Public Health Rep       Date:  2001       Impact factor: 2.792

10.  A randomized controlled trial of venlafaxine XR for major depressive disorder after spinal cord injury: Methods and lessons learned.

Authors:  Charles H Bombardier; Jesse R Fann; Catherine S Wilson; Allen W Heinemann; J Scott Richards; Ann Marie Warren; Larry Brooks; Catherine A Warms; Nancy R Temkin; Denise G Tate
Journal:  J Spinal Cord Med       Date:  2013-11-26       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.